Tenecteplase is a recombinant, genetically engineered variant of human tissue-type plasminogen activator (tPA) and is classified as a fibrinolytic or thrombolytic biologic. It binds preferentially to fibrin within thrombi and converts plasminogen to plasmin, resulting in degradation of the fibrin matrix of blood clots.
Tenecteplase is a 527-amino-acid glycoprotein derived from human tissue plasminogen activator. Its molecular engineering includes substitution of threonine at position 103 with asparagine, substitution of asparagine at position 117 with glutamine, and replacement of amino acids 296–299 with four alanine residues. These modifications provide important functional properties including increased fibrin specificity and resistance to plasminogen activator inhibitor-1 compared with native tPA.
The API is used in the development and manufacture of thrombolytic medicines intended for conditions in which rapid dissolution of pathological blood clots is clinically required.
PubChem identifies CAS 191588-94-0 and FDA UNII WGD229O42W for tenecteplase and describes it as a 527-amino-acid modified form of human tissue plasminogen activator.
Unlike conventional chemical APIs, tenecteplase is a complex recombinant protein whose quality is determined through a combination of structural, physicochemical and biological assays. A single molecular-weight value is therefore not an appropriate replacement for a complete protein characterization package.
Tenecteplase contains natural amino acids and carbohydrate components and is formulated as a protein drug substance. EMA describes the drug substance as being formulated in an arginine/phosphate buffer system with polysorbate 20 for the marketed drug product.
The protein has an experimentally reported isoelectric point of approximately 7.61 in PubChem's referenced data. PubChem also lists a reported melting-point value of 60°C, but this should be treated only as an experimental/reference physical property and not as a pharmaceutical API release specification.
Tenecteplase functions as a fibrin-specific plasminogen activator. It preferentially binds to fibrin within a thrombus and catalyses conversion of plasminogen to plasmin. Plasmin subsequently breaks down the fibrin network that maintains the blood clot.
This mechanism provides the pharmacological basis for its use as a thrombolytic agent in acute ischemic vascular events.
Tenecteplase is used in thrombolytic therapy and is authorized in the European Union for:
The EMA currently lists tenecteplase under the antithrombotic pharmacotherapeutic group and ATC code B01AD11.
Because Tenecteplase is a recombinant biologic API, quality control differs substantially from conventional synthetic APIs.
EMA documentation identifies the following analytical controls for the tenecteplase product:
EMA states that the analytical procedures for the drug product correspond to the analytical procedures used for the drug substance.
Tenecteplase is manufactured using recombinant biotechnology rather than conventional chemical synthesis. Manufacturing controls therefore focus on cell-culture/process consistency, purification, viral and microbial controls, protein structural integrity, aggregation, product-related variants and biological activity.
The final drug product is produced as a lyophilized preparation. EMA documentation confirms that the same tenecteplase drug substance is used across the 25 mg, 40 mg and 50 mg presentations.
For the approved lyophilized product, EMA describes a Type I borosilicate glass vial with a coated rubber stopper and aluminium crimp cap. The reported shelf life for the 25 mg presentation is 36 months when stored at temperatures not above 30°C. In-use stability is reported as up to 24 hours at 2–8°C or up to 8 hours at 30°C under the specified conditions.
For bulk Tenecteplase API/drug substance, the actual storage temperature, container configuration and allowable hold time should follow the manufacturer's validated drug-substance specification and stability program.
A professional Tenecteplase API manufacturer should maintain appropriate documentation such as:
Tenecteplase requires specialized recombinant-biologics manufacturing and analytical capabilities. A qualified manufacturing program should demonstrate control of protein identity, purity, aggregation, structural heterogeneity, potency, microbial quality and product consistency.
For pharmaceutical development and commercial manufacturing, Tenecteplase API should therefore be evaluated using a biologic-specific specification package rather than a generic synthetic-API specification template.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |